# Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

> **NCT04880993** · PHASE1 · COMPLETED · sponsor: **Jiangsu Hansoh Pharmaceutical Co., Ltd.** · enrollment: 30 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** Dapagliflozin 10 mg tablets
- **DRUG:** Farxiga® 10 mg tablets

## Key facts

- **NCT ID:** NCT04880993
- **Lead sponsor:** Jiangsu Hansoh Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2020-12-24
- **Final completion:** 2021-02-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2021-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880993, "Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04880993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*